Pemvidutide (TFA)

• Description :

  Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research[1].

• Product Name Alternative :

  ALT-801 (TFA)

• UNSPSC :

  12352209

• Target :

  GCGR; GLP Receptor

• Related Pathways :

  GPCR/G Protein

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Purity :

  98.07

• Solubility :

  H2O : ≥ 50 mg/mL

• Smiles :

  O=C([C@@H](N)CC1=CNC=N1)NC(C)(C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)[C@@H](C)O)=O)CCC(N)=O)=O)CC(C)C)=O)CC(C)C)=O)CC2=CNC3=CC=CC=C23)=O)CCC(N)=O)=O)[C@H](CC)C)=O)CC4=CC=CC=C4)=O)CCC(O)=O)=O)CCCCN5)=O)C)=O)C)=O)CCCCNC([C@@H]6[C@H]([C@@H]([C@H]([C@@H](O6)OCCCCCCCCCCCCCCCCCC(O)=O)O)O)O)=O)=O)CCC5=O)=O)CC(O)=O)=O)CC(C)C)=O)CC7=CC=C(O)C=C7)=O)CCCCN)=O)CO)=O)CC8=CC=C(O)C=C8)=O)CC(O)=O)=O)CO)=O)[C@@H](C)O)=O)CC9=CC=CC=C9)=O)[C@@H](C)O)=O)=O)CCC(N)=O)=O)C.O=C(C(F)(F)F)O.[x]

• Molecular Formula :

  C182H275N39O54.xC2HF3O2

• Molecular Weight :

  3873.35 (free base)

• References & Citations :

  [1]Yabut JM, et al. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev. 2022 Jul 30:bnac018.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category :

  Peptides

• Clinical Information :

  Phase 2